Cargando…
DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial
INTRODUCTION: Saphenous vein grafts (SVGs) remain the most often used conduits in coronary artery bypass grafting (CABG). However, they are prone to vein graft disease (VGD) during follow-up, which may compromise clinical outcomes. Injury to the SVG endothelium during harvesting and storage promotes...
Autores principales: | Ben Ali, Walid, Voisine, Pierre, Olsen, Peter Skov, Jeanmart, Hugues, Noiseux, Nicolas, Goeken, Tracy, Satishchandran, Vilas, Cademartiri, Filippo, Cutter, Garry, Veerasingam, Dave, Brown, Craig, Emmert, Maximilian Y, Perrault, Louis P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905829/ https://www.ncbi.nlm.nih.gov/pubmed/29682294 http://dx.doi.org/10.1136/openhrt-2018-000780 |
Ejemplares similares
-
A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry
por: Caliskan, Etem, et al.
Publicado: (2019) -
Graft Preservation Solution DuraGraft(®) Alleviates Vascular Dysfunction Following In Vitro Ischemia/Reperfusion Injury in Rats
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021) -
The obstinate question of vein graft versus arterial conduits
por: Bhushan, Rahul, et al.
Publicado: (2023) -
Sleep apnoea and cardiovascular outcomes after coronary artery bypass grafting
por: Koo, Chieh Yang, et al.
Publicado: (2020) -
Preoperative disturbances of glucose metabolism and mortality after coronary artery bypass grafting
por: Djupsjo, Catarina, et al.
Publicado: (2020)